Biologic agents in the treatment of rheumatic diseases with chronic viral infection. Where are we?

Journal of Rheumatology

Volumn 36, Issue 6, 2009, Pages 1107-1108

  Wendling, Daniel ^a   Di Martino, Vincent ^a   Herbein, Georges ^a  

^a UNIVERSITY HOSPITAL OF BESANÇON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ADEFOVIR; ATLIZUMAB; ENTECAVIR; ETANERCEPT; HEPATITIS B CORE ANTIGEN; HEPATITIS B SURFACE ANTIGEN; INFLIXIMAB; LAMIVUDINE; RITUXIMAB; TENOFOVIR; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; CHRONIC DISEASE; DRUG EFFICACY; EDITORIAL; FOLLOW UP; HEPATITIS B; HUMAN; LYMPHOMA; MEDICAL DECISION MAKING; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; TREATMENT OUTCOME; VIRUS INFECTION; VIRUS LOAD; VIRUS REPLICATION;

ANTIRHEUMATIC AGENTS; BIOLOGICAL PRODUCTS; CHRONIC DISEASE; HUMANS; IMMUNOCOMPROMISED HOST; IMMUNOSUPPRESSIVE AGENTS; RHEUMATIC DISEASES; TUMOR NECROSIS FACTOR-ALPHA; VIRUS DISEASES;

EID: 67149130598     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: 10.3899/jrheum.090119     Document Type: Editorial

References (21)

1. Patkar NM, Teng GG, Curtis JR, et al. Association of infections and tuberculosis with anti-tumor necrosis factor alpha therapy. Curr Opin Rheumatol 2008;20:320-326
2. Wendling D, Herbein G. TNF-alpha antagonist therapy in patients with joint disease and chronic viral infection. Joint Bone Spine 2007;74:407-409 (Pubitemid 47628751)
3. Zingarelli S, Frassi M, Bazzani C, et al. Use of tumor necrosis alpha-blocking agents use in hepatitis B virus-positive patients. Reports of 3 cases and review of the literature. J Rheumatol 2009;36:1188-1194
4. Narvaez J, Rodriguez-Moreno J, Martinez-Aguila MD, Clavaguera MT. Severe hepatitis linked to B virus infection after withdrawal of low dose methotrexate therapy. J Rheumatol 1998;25:2037-2038 (Pubitemid 28459328)
5. Ito S, Nakazono K, Murazawa A, et al. Development of fulminant hepatitis B (precore variant mutant type) after the discontinuation of low-dose methotrexate therapy in a rheumatoid arthritis patient. Arthritis Rheum 2001;44:339-342 (Pubitemid 32207027)
6. Thiefin G, Morelet A, Heurgué A, et al. Infliximab-induced hepatitis: Absence of cross-toxicity with etanercept. Joint Bone Spine 2008;75:737-739
7. Pham T, Claudepierre P, Deprez X, et al; Club Rhumatismes et Inflammation, French Society of Rheumatology. Anti-TNF alpha therapy and safety monitoring. Clinical tool guide elaborated by the Club Rhumatismes et Inflammations (CRI), section of the French Society of Rheumatology (Société Française de Rhumatologie, SFR). Joint Bone Spine 2005;72 Suppl 1:S1-58.
8. Herbein G, O'Brien WA. Tumor necrosis factor (TNF)-alpha and TNF receptors in viral pathogenesis. Proc Soc Exp Biol Med 2000;223:241-257 (Pubitemid 30337778)
9. Wendling D, Di Martino V, Prati C, et al. Spondyloarthropathy and chronic B hepatitis. Effect of anti-TNF therapy. Joint Bone Spine; doi:10.1016/j. jbspin.2008
10. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B. J Hepatol 2009;50:227-242
11. Benhamou Y, Bochet M, Thibault V, et al. Long-term incidence of hepatitis B virus resistance to lamivudine in human immunodeficiency virus-infected patients. Hepatology 1999;30:1302-1306 (Pubitemid 29510871)
12. Nagashima T, Minota S. Long-term tocilizumab therapy in a patient with rheumatoid arthritis and chronic hepatitis B. Rheumatology 2008;47:1838-1840
13. Cansu DU, Kalifoglu T, Korkmaz C. Short-term course of chronic hepatitis B and C under treatment with etanercept associated with different disease modifying antirheumatic drugs without antiviral prophylaxis. J Rheumatol 2008;35:421-424
14. Montiel PM, Solis JA, Chirinos JA, et al. Hepatitis B virus reactivation during therapy with etanercept in an HBsAg-negative and anti-HBs-positive patient. Liver Int 2008;28:718-720 (Pubitemid 351541107)
15. Charpin CH, Guis S, Colson P, et al. A monitoring of patients with hepatitis B serological pattern indicating past infection and treated by TNF á inhibitor for inflammatory rheumatism: preliminary results [abstract]. Arthritis Rheum 2008;58 Suppl:S558.
16. Wendling D, Streit G, Toussirot E, Prati C. Herpes zoster during anti TNF treated chronic artrhitis. Joint Bone Spine 2008;75:540-543
17. Khaled Y, Hanbali A. Hepatitis B virus reactivation in a case of Waldenstrom's macroglobulinemia treated with chemotherapy and rituximab despite adefovir prophylaxis. Am J Hematol 2007;82:688. (Pubitemid 47015308)
18. Yang SH, Kuo SH. Reactivation of hepatitis B virus during rituximab treatment of a patient with follicular lymphoma. Ann Hematol 2008;87:325-327
19. Rodriguez-Escalera C, Fernández-Nebro A. The use of rituximab to treat a patient with ankylosing spondylitis and hepatitis B. Rheumatology 2008;47:1732-1733
20. Aksoy S, Harputuoglu H, Kilickap S, et al. Rituximab related viral infections in lymphoma patients. Leuk Lymphoma 2007;48:1307-1312 (Pubitemid 47079357)
21. Pham T, Fautrel B, Gottenberg JE, et al; Rheumatic Diseases and Inflammation Group (Club Rhumatismes et Inflammation, CRI) of the French Society for Rheumatology (Société Française de Rhumatologie, SFR). Rituximab (MabThera) therapy and safety management. Clinical tool guide. Joint Bone Spine 2008;75 Suppl 1:S1-99.